204 related articles for article (PubMed ID: 22450359)
1. [PARP inhibitors and breast cancer: update and perspectives].
Gonçalves A
Bull Cancer; 2012 Apr; 99(4):441-51. PubMed ID: 22450359
[TBL] [Abstract][Full Text] [Related]
2. [From poly(ADP-ribose) discovery to PARP inhibitors in cancer therapy].
Schreiber V; Illuzzi G; Héberlé E; Dantzer F
Bull Cancer; 2015 Oct; 102(10):863-73. PubMed ID: 26384693
[TBL] [Abstract][Full Text] [Related]
3. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study.
Gelmon KA; Tischkowitz M; Mackay H; Swenerton K; Robidoux A; Tonkin K; Hirte H; Huntsman D; Clemons M; Gilks B; Yerushalmi R; Macpherson E; Carmichael J; Oza A
Lancet Oncol; 2011 Sep; 12(9):852-61. PubMed ID: 21862407
[TBL] [Abstract][Full Text] [Related]
4. Advances in PARP inhibitors for the treatment of breast cancer.
Dizdar O; Arslan C; Altundag K
Expert Opin Pharmacother; 2015; 16(18):2751-8. PubMed ID: 26485111
[TBL] [Abstract][Full Text] [Related]
5. PARP inhibitors in breast cancer: BRCA and beyond.
Rios J; Puhalla S
Oncology (Williston Park); 2011 Oct; 25(11):1014-25. PubMed ID: 22106552
[TBL] [Abstract][Full Text] [Related]
6. [PARP inhibitors--theoretical basis and clinical application].
Dębska S; Kubicka J; Czyżykowski R; Habib M; Potemski P
Postepy Hig Med Dosw (Online); 2012 May; 66():311-21. PubMed ID: 22706117
[TBL] [Abstract][Full Text] [Related]
7. PARP inhibition in BRCA-mutated breast and ovarian cancers.
Chan SL; Mok T
Lancet; 2010 Jul; 376(9737):211-3. PubMed ID: 20656109
[No Abstract] [Full Text] [Related]
8. The role of poly adenosine diphosphate ribose polymerase inhibitors in breast and ovarian cancer: current status and future directions.
Chionh F; Mitchell G; Lindeman GJ; Friedlander M; Scott CL
Asia Pac J Clin Oncol; 2011 Sep; 7(3):197-211. PubMed ID: 21884432
[TBL] [Abstract][Full Text] [Related]
9. [PARP inhibitors: new therapeutic agents in breast and ovarian cancer].
Mercier-Vogel L; Bodmer A; Castiglione M
Rev Med Suisse; 2011 May; 7(296):1137-40. PubMed ID: 21721203
[TBL] [Abstract][Full Text] [Related]
10. PARP inhibitors in ovarian cancer: current status and future promise.
Liu JF; Konstantinopoulos PA; Matulonis UA
Gynecol Oncol; 2014 May; 133(2):362-9. PubMed ID: 24607283
[TBL] [Abstract][Full Text] [Related]
11. High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs.
Rottenberg S; Jaspers JE; Kersbergen A; van der Burg E; Nygren AO; Zander SA; Derksen PW; de Bruin M; Zevenhoven J; Lau A; Boulter R; Cranston A; O'Connor MJ; Martin NM; Borst P; Jonkers J
Proc Natl Acad Sci U S A; 2008 Nov; 105(44):17079-84. PubMed ID: 18971340
[TBL] [Abstract][Full Text] [Related]
12. Poly(ADP-ribose) polymerase inhibition: a new direction for BRCA and triple-negative breast cancer?
Plummer R
Breast Cancer Res; 2011 Aug; 13(4):218. PubMed ID: 21884642
[TBL] [Abstract][Full Text] [Related]
13. PARP inhibitors: its role in treatment of cancer.
Chen A
Chin J Cancer; 2011 Jul; 30(7):463-71. PubMed ID: 21718592
[TBL] [Abstract][Full Text] [Related]
14. [Cancer therapy by PARP inhibitors].
Seimiya H
Nihon Rinsho; 2015 Aug; 73(8):1330-5. PubMed ID: 26281686
[TBL] [Abstract][Full Text] [Related]
15. [Hereditary ovarian carcinomas: clinico-biological features and treatment].
Floquet A; Stoeckle E; Croce S; Longy M; Mc Grogan G; Barouk E; Bubien V; Garbay D; Joly E; Guyon F
Bull Cancer; 2014 Feb; 101(2):167-74. PubMed ID: 24555961
[TBL] [Abstract][Full Text] [Related]
16. PARP inhibitors: targeting the right patients.
Azvolinsky A
J Natl Cancer Inst; 2012 Dec; 104(24):1851-2. PubMed ID: 23231976
[No Abstract] [Full Text] [Related]
17. Combination treatment using DDX3 and PARP inhibitors induces synthetic lethality in BRCA1-proficient breast cancer.
Heerma van Voss MR; Brilliant JD; Vesuna F; Bol GM; van der Wall E; van Diest PJ; Raman V
Med Oncol; 2017 Mar; 34(3):33. PubMed ID: 28138868
[TBL] [Abstract][Full Text] [Related]
18. BRCA-deficient and triple negative breast cancers: is olaparib effective in both subtypes?
Sahin I; Ararat E; Altundag K
J BUON; 2011; 16(1):184-5. PubMed ID: 21674877
[No Abstract] [Full Text] [Related]
19. [PARP inhibitors to treat triple negative breast cancer].
Sugie T
Gan To Kagaku Ryoho; 2010 Dec; 37(13):2850-5. PubMed ID: 21235091
[No Abstract] [Full Text] [Related]
20. PARP inhibitors in breast cancer.
Telli ML; Ford JM
Clin Adv Hematol Oncol; 2010 Sep; 8(9):629-35. PubMed ID: 21157412
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
